AUTHORS
Peter Tonzi, MD, PhD, Giulia Cheloni, PhD2, Dimitra Karagkouni, PhD3, Shivani Nanda4, Richard M. Stone, MD5, Kai W. Wucherpfennig, MD, PhD6, Aric Hall, MD7, Amir T. Fathi, MD8, Lina Bisharat, MSc9, Emma Logan, MSN10, Maxime Meylan11, Yiwen Liu, MS12, Donna Neuberg, ScD13, Malgorzata McMasters, MD14, Jessica Liegel, MD15, Jacqueline S. Garcia, MD16, Daniel J DeAngelo, MD, PhD17, Yuling Ma18, Athanasios Ploumakis19, Sheethal Nagalakshmi20, Michele Narcis21, Dina Stroopinsky, PhD22, Prateek Pophali23, Ioannis Vlachos, PhD24, Ilene Galinsky, ANP25, Hazal Toros26, Haitham Abdelhakim, MD27, Amelia Langston, MD28, Joseph P McGuirk, DO29, Donald Kufe30, David E. Avigan, MD31, Jacalyn Rosenblatt, MD32
AFFILIATIONS
1 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
2 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
3 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
4 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 University of Wisconsin, Madison, Wisconsin, United States
8 Massachusetts General Hospital, Boston, Massachusetts, United States
9 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
15 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
19 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
20 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
21 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
22 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
23 Brown University Health, Providence, Rhode Island, United States
24 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
25 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
26 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
27 University of Kansas Medical Center, Kansas City, Kansas, United States
28 Emory University School of Medicine, Atlanta, Georgia, United States
29 University of Kansas Medical Center, Kansas City, Kansas, United States
30 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
31 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
32 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
ABSTRACT
We have developed a personalized dendritic cell (DC)/AML fusion vaccine platform in which patient-derived AML cells are fused with autologous ex-vivo generated dendritic cells. In this way, a broad array of tumor antigens, including shared antigens, neoantigens, and subclonal leukemia-associated antigens can be presented in the context of DC derived co-stimulation. We completed a randomized phase II clinical study (NCT03059485) in which patients with AML who achieve complete remission (CR) with 7+3 or hypomethylating agent (HMA)/venetoclax (ven) were randomized to receive DC/AML fusion vaccine versus standard of care (SOC) therapy. The trial was powered to randomize 75 patients, however due to the emergence of targeted agents into the SOC therapy for AML, the protocol was closed prematurely to evaluate clinical and immune endpoints and plan for incorporation of targeted therapy into future trial design. Here we report the safety, efficacy and correlative laboratory results from the cohort of 41 enrolled patients.
Eligible patients were >55 years who were not candidates for allogeneic transplant and achieved a CR/CRi with 7+3 or HMA/ven. The primary endpoint was 2-year progression free survival (PFS). Patients were enrolled at diagnosis, stratified by treatment (chemotherapy or HMA/ven), and randomized 2:1 to the vaccine or SOC after induction. All patients received consolidation with up to 4 cycles of chemotherapy or up to 8 cycles of HMA/ven. Patients in the vaccine arm then received 3 doses of vaccine every 4-8 weeks, and did not receive further leukemia directed therapy from the time of starting vaccination.
A total of 41 patients with median age 68 years (range 55-86) were randomized, 27 to vaccination and 14 to SOC. Two patients (one in each arm) withdrew consent and were not followed for response or survival. Three patients were considered ineligible to proceed with vaccine generation. A total of 74% of vaccine eligible patients received 3 doses of vaccine. ELN 2022 favorable, intermediate, and adverse risks were 37%, 30%, and 33% in the vaccine arm, and 50%, 14%, 36% in the SOC arm. In both arms, 77% patients received chemotherapy and 23% HMA/ven. The 2-year and 5-year PFS was 46% (95% CI: 28.7%, 63.3%) and 25% for vaccinated patients and 25% (95% CI: 10.9%, 58.7%) and 12% for patients receiving standard of care.
Single cell gene expression was performed on bone marrow samples collected in remission pre and 1-month post vaccination from patients in the vaccine (N=11) and SOC (N=4) arms. An increase in CD4 T helper cells and CD8 cytotoxic T cells was observed in the vaccinated patients compared with control. T cell receptor repertoire analysis in peripheral blood samples from vaccine (N=7) and SOC (N=3) revealed both clonotype expansion and generation of de novo clones at 3-months post-vaccine compared to pre-vaccine. For the expanding clonotypes, vaccinated patients had statistically significant increase in oligoclonal expansion by Simpson’s diversity index compared to control.
To identify features of the marrow immune microenvironment associated with vaccine-mediated disease control, we performed spatial profiling of bone marrow samples obtained at baseline, pre-vaccine, and one month after vaccination from patients who achieved durable remission compared with those who relapsed (N=8). Remission was associated with enrichment of proliferating cytotoxic CD8 T cells. Relapse was associated with a higher proportion of suppressive tumor-associated macrophages (TAM). Suppressive myeloid cells including TAMs and myeloid derived suppressor cells (MDSCs) formed extensive, spatially contiguous hubs in relapsing marrow but were sparse and scattered in remission. TAM-MDSC and TAM-TAM co-localization were enriched in relapse and increased following vaccination, suggesting that macrophage-dominated suppressive niches may limit effective T cell priming and antileukemia immunity.
In summary, immunological response to DC/AML fusion vaccination was characterized by emergence and persistence of specific T cell clonotypes. In the absence of maintenance therapy, the vaccine was associated with 2-year PFS of 46% and OS of 81% in older patients in CR1. Ongoing studies include identifying markers of response to vaccination using single cell and spatial data, analyzing expanded T cell clones as a means for antigen discovery and evaluation of an adoptive T cell therapy using vaccine primed T cells in a recently activated clinical trial.
DISCLOSURES
Peter Tonzi, MD, PhD: No relevant conflicts of interest to declare.